- Home
- WSFS vs RCUS Comparison
WSFS vs RCUS Comparison
Compare WSFS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSFS | RCUS |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WSFS | RCUS |
|---|---|---|
| Price | $56.44 | $21.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $64.25 | $29.00 |
| AVG Volume (30 Days) | 408.6K | ★ 2.0M |
| Earning Date | 01-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ 9.94 | N/A |
| EPS | ★ 4.83 | N/A |
| Revenue | ★ $1,011,052,000.00 | $240,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | $11.85 | ★ N/A |
| Revenue Growth | ★ 4.02 | N/A |
| 52 Week Low | $42.44 | $6.50 |
| 52 Week High | $59.67 | $26.40 |
Technical Indicators
Market Signals| Indicator | WSFS | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 41.30 |
| Support Level | $54.31 | $20.59 |
| Resistance Level | $57.61 | $23.40 |
| Average True Range (ATR) | 1.03 | 1.15 |
| MACD | -0.10 | -0.29 |
| Stochastic Oscillator | 57.74 | 13.04 |
Price Performance
Historical ComparisonAbout WSFS WSFS Financial Corporation
WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.